Dygase Side Effects
Generic name: pancrelipase
Note: This document contains side effect information about pancrelipase. Some of the dosage forms listed on this page may not apply to the brand name Dygase.
Some side effects of Dygase may not be reported. Always consult your doctor or healthcare specialist for medical advice. You may also report side effects to the FDA.
For the Consumer
Applies to pancrelipase: oral capsule, oral capsule delayed release, oral powder, oral tablet, oral tablet chewable
Along with its needed effects, pancrelipase (the active ingredient contained in Dygase) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.
Check with your doctor immediately if any of the following side effects occur while taking pancrelipase:Rare
- Skin rash or hives
- Bowel blockage
- stomach cramps or pain
- Blood in the urine
- joint pain
- swelling of the feet or lower legs
- Shortness of breath
- stuffy nose
- tightness in the chest
- trouble breathing
- Irritation of the mouth
- difficulty with swallowing
- fast heartbeat
- noisy breathing
- puffiness or swelling of the eyelids or around the eyes, face, lips, or tongue
- redness of the skin
- severe stomach pain
- unusual tiredness or weakness
Some side effects of pancrelipase may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects. Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:More common
- Blurred vision
- dry mouth
- flushed, dry skin
- fruit-like breath odor
- increased hunger
- increased thirst
- increased urination
- unexplained weight loss
- Abnormal feces
- cold sweats
- cool, pale skin
- excess air or gas in the stomach or intestines
- frequent bowel movements
- full feeling
- muscle aches
- passing gas
- runny nose
- slurred speech
- sore throat
- Difficulty having a bowel movement (stool)
- difficulty with moving
- muscle aching or cramping
- muscle pains or stiffness
- muscle spasm
- swollen joints
For Healthcare Professionals
Applies to pancrelipase: oral capsule, oral capsule extended release, oral delayed release capsule, oral powder for reconstitution, oral tablet, oral tablet extended release
In general, pancreatic enzymes are well tolerated at recommended therapeutic doses. Gastrointestinal symptoms appear to be the primary, and most common adverse effect.
Fibrosing colonopathy should be suspected in patients who present with obstruction, bloody diarrhea, chylous ascites, or a combination of abdominal pain with chronic diarrhea, inadequate weight gain, or both. Patients with fibrosing colonopathy should have their enzyme dosage reduced to the recommended range of 500 to 2500 units/kg per meal. Surgical intervention is often needed in patients who cannot maintain their nutritional status.
Gastrointestinal side effects have included cramping, nausea, abnormal feces, flatulence, abdominal pain, upper abdominal pain, and diarrhea, particularly with high doses. Fibrosing colonopathy has been reported. Animal studies suggest that the fibrosing colonopathy seen in some patients receiving high doses of pancreatic enzymes may be due to a plasticizer (methacrylic acid copolymer) found in some of the enteric coatings. Postmarketing reports have included abdominal distention, abdominal pain, diarrhea, flatulence, constipation, nausea, fibrosing colonopathy, and distal intestinal obstruction syndrome (DIOS).
Metabolic side effects reported with high doses of pancreatic enzymes have included hyperuricosuria and hyperuricemia. It appears that both the enzyme product and some undefined aspect of the disease may lead to increased uric acid levels. Postmarketing reports of inadequate control of diabetes mellitus have been reported.
Krasinger and colleagues suggest that it may be reasonable to add allopurinol to the pancreatic enzyme treatment regimen in CF patients that have a urine pH of less than 6 and also excrete large amounts of uric acid. The addition of allopurinol may help to protect the renal tubules from long-term damage due to uric acid crystallization.
Hypersensitivity side effects have included reversible bronchial asthma and nasal rhinitis due to exposure to pancreatic enzyme powder. Postmarketing severe allergic reactions including anaphylaxis, asthma, hives and pruritus have been reported.
Local side effects have included ulcerations and stomatitis after a prolonged retention of pancreatic enzyme formulations in the mouth.
Nervous system side effects have included several case reports of elevation in intracranial pressure (leading to a bulging cranial fontanelle) in cystic fibrosis children receiving pancreatic enzymes. The adverse effect has been self-limiting without interruption of cystic fibrosis therapy in most cases.
Postmarketing side effects include pruritus, urticaria and rash
Postmarketing side effects include recurrence of pre-existing carcinoma.
More Dygase resources
- Dygase MedFacts Consumer Leaflet (Wolters Kluwer)
- pancrelipase MedFacts Consumer Leaflet (Wolters Kluwer)
- Pancrelipase Prescribing Information (FDA)
- Pancrelipase Monograph (AHFS DI)
- Pancrelipase Professional Patient Advice (Wolters Kluwer)
- Creon Prescribing Information (FDA)
- Creon Consumer Overview
- Creon Advanced Consumer (Micromedex) - Includes Dosage Information
- Creon MedFacts Consumer Leaflet (Wolters Kluwer)
- Creon 10 delayed-release capsules MedFacts Consumer Leaflet (Wolters Kluwer)
- Pancreaze Consumer Overview
- Pancreaze Prescribing Information (FDA)
- Pertzye Consumer Overview
- Pertzye delayed-release capsules MedFacts Consumer Leaflet (Wolters Kluwer)
- Pertzye Prescribing Information (FDA)
- Ultresa Prescribing Information (FDA)
- Ultresa delayed-release capsules MedFacts Consumer Leaflet (Wolters Kluwer)
- Ultresa Consumer Overview
- Viokace Prescribing Information (FDA)
- Viokace Consumer Overview
- Viokace MedFacts Consumer Leaflet (Wolters Kluwer)
- Zenpep Prescribing Information (FDA)
- Zenpep Consumer Overview
Disclaimer: Every effort has been made to ensure that the information provided is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This information does not endorse drugs, diagnose patients, or recommend therapy. This drug information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective, or appropriate for any given patient. Drugs.com does not assume any responsibility for any aspect of healthcare administered with the aid of information provided. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.